Literature DB >> 20805295

Pulmonary outcome in juvenile dermatomyositis: a case-control study.

Helga Sanner1, Trond Mogens Aaløkken, Jan Tore Gran, Ivar Sjaastad, Bjørn Johansen, Berit Flatø.   

Abstract

OBJECTIVES: To compare pulmonary function in patients with juvenile dermatomyositis (JDM) with that of matched controls; and to examine associations between pulmonary function impairment, high-resolution CT (HRCT) abnormalities and other disease variables in patients with JDM.
METHODS: A total of 59 patients with JDM clinically examined a median 16.8 years (range 2-38 years) after disease onset were compared with 59 age-matched and sex-matched controls. Pulmonary function tests included spirometry, diffusing capacity for carbon monoxide (DLCO) and body plethysmography. In patients with JDM, HRCT scans were performed and cumulative organ damage and patient-reported health status assessed.
RESULTS: Patients with JDM had lower total lung capacity (TLC) and DLCO compared to controls (p=0.003 and <0.001, respectively). A low TLC was found in 26% of patients versus 9% of controls (p=0.026), and a low DLCO in 49% of patients versus 9% of controls (p<0.001). HRCT abnormalities were found in 37% of patients, and included interstitial lung disease (ILD) (14%), chest wall calcinosis (14%) and airway disease (15%). Three patients were diagnosed as having ILD prior to the follow-up visit. A low TLC was more often found in patients with than without abnormal HRCT (50% vs 12%, p=0.002). HRCT abnormality correlated with cumulative organ damage (r(s)=0.346, p=0.008) and patient-reported health status at follow-up (p<0.005).
CONCLUSIONS: Patients with JDM had smaller lung volumes than controls; a restrictive ventilatory defect was found in 26% and HRCT abnormality in 37% of the patients, and these findings were associated. Although mostly subclinical, the relatively high frequency of pulmonary involvement highlights the systemic nature of JDM.

Entities:  

Mesh:

Year:  2010        PMID: 20805295     DOI: 10.1136/ard.2010.131433

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Dramatic heliotrope dermatitis and uncommon pulmonary involvement in juvenile dermatomyositis.

Authors:  Yang Jiao; Xuejun Zeng
Journal:  BMJ Case Rep       Date:  2012-01-10

Review 2.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 4.  Rare Lung Diseases: Interstitial Lung Diseases and Lung Manifestations of Rheumatological Diseases.

Authors:  Mahesh Babu Ramamurthy; Daniel Y T Goh; Michael Teik Chung Lim
Journal:  Indian J Pediatr       Date:  2015-08-20       Impact factor: 1.967

Review 5.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

6.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

7.  Associations between cardiac and pulmonary involvement in patients with juvenile dermatomyositis-a cross-sectional study.

Authors:  Birgit Nomeland Witczak; Thomas Schwartz; Zoltan Barth; Eli Taraldsrud; May Brit Lund; Trond Mogens Aaløkken; Berit Flatø; Ivar Sjaastad; Helga Sanner
Journal:  Rheumatol Int       Date:  2022-01-04       Impact factor: 3.580

8.  Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

Authors:  Sarah L Tansley; Zoe E Betteridge; Harsha Gunawardena; Thomas S Jacques; Catherine M Owens; Clarissa Pilkington; Katie Arnold; Shireena Yasin; Elena Moraitis; Lucy R Wedderburn; Neil J McHugh
Journal:  Arthritis Res Ther       Date:  2014-07-02       Impact factor: 5.156

Review 9.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?

Authors:  Sarah L Tansley; Neil J McHugh; Lucy R Wedderburn
Journal:  Arthritis Res Ther       Date:  2013-04-08       Impact factor: 5.156

10.  Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage.

Authors:  Helga Sanner; Thomas Schwartz; Berit Flatø; Maria Vistnes; Geir Christensen; Ivar Sjaastad
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.